BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38604310)

  • 1. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
    Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
    Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
    Wagner J; Wickman E; DeRenzo C; Gottschalk S
    Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms of resistance and escape to CAR-T cells].
    Grinda T; Brouard J; Tran D; Rubio MT
    Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
    Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO
    Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-Ts: new perspectives in cancer therapy.
    Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
    FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors.
    Yuan G; Ye M; Zhang Y; Zeng X
    Med Oncol; 2024 Apr; 41(5):126. PubMed ID: 38652178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
    Schwerdtfeger M; Benmebarek MR; Endres S; Subklewe M; Desiderio V; Kobold S
    Curr Hematol Malig Rep; 2021 Apr; 16(2):218-233. PubMed ID: 33939108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
    Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M
    Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
    Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
    J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.